Heron Therapeutics, Inc.
HRTX
$0.84
-$0.03-3.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.59M | 38.21M | 37.20M | 38.90M | 40.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.59M | 38.21M | 37.20M | 38.90M | 40.78M |
| Cost of Revenue | 3.47M | 15.38M | 12.79M | 10.74M | -1.42M |
| Gross Profit | 37.12M | 22.83M | 24.41M | 28.17M | 42.20M |
| SG&A Expenses | 25.69M | 26.92M | 26.05M | 25.01M | 23.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.55M | 42.31M | 38.84M | 35.75M | 36.61M |
| Operating Income | 38.00K | -4.09M | -1.64M | 3.15M | 4.17M |
| Income Before Tax | -2.95M | -17.50M | -2.38M | 2.64M | 3.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.95M | -17.50M | -2.38M | 2.64M | 3.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.95M | -17.50M | -2.38M | 2.64M | 3.66M |
| EBIT | 38.00K | -4.09M | -1.64M | 3.15M | 4.17M |
| EBITDA | 575.00K | -3.48M | -1.03M | 3.71M | 4.75M |
| EPS Basic | -0.02 | -0.10 | -0.02 | 0.02 | 0.02 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.01 | 0.01 | 0.02 |
| EPS Diluted | -0.02 | -0.10 | -0.02 | 0.01 | 0.02 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.01 | 0.01 | 0.02 |
| Average Basic Shares Outstanding | 188.03M | 170.35M | 154.02M | 153.49M | 153.15M |
| Average Diluted Shares Outstanding | 188.03M | 170.35M | 154.02M | 196.92M | 153.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |